Dashboard
Financial statements
PFE

Company financials

Pfizer

Health Care Pharmaceuticals New York City, New York Last filing Feb 26, 2026 · FY2025
Revenue FY2025
$62.6B
Net income FY2025
$7.8B

Balance Sheet

Assets, liabilities, and equity

31 accounts · 5 years
Account 2025 2024 2023 2022 2021
Statement
BS Assets Cash $1.1B $1.0B $2.9B $416.0M $1.9B
BS Assets Short Term Invest $9.2B $10.9B $4.4B $18.7B $22.0B
BS Assets Accts Receivable $11.9B $11.5B $11.2B $11.0B $11.5B
BS Assets Inventory $10.7B $10.9B $10.2B $9.0B $9.1B
BS Assets Prepaid Expenses $2.8B $4.3B $5.3B $5.0B $3.8B
BS Assets Other Current Assets $2.8B $4.3B $5.3B $5.0B $3.8B
BS Assets Total Current $42.9B $50.4B $43.3B $51.3B $59.7B
BS Assets PPE $19.3B $18.4B $18.9B $16.3B $14.9B
BS Assets Goodwill $71.3B $68.5B $67.8B $51.4B $49.2B
BS Assets Intangible Assets $53.7B $55.4B $64.9B $43.4B $25.1B
BS Assets LT Investments $1.6B $2.2B $15.4B $15.1B $21.5B
BS Assets Other Noncurrent $9.6B $9.8B $12.5B $13.2B $7.7B
BS Assets Total $208.2B $213.4B $226.5B $197.2B $181.5B
BS Liab Accts Payable $5.2B $5.6B $6.7B $6.8B $5.6B
BS Liab Accrued Liab $6.1B $6.3B $5.1B $5.7B $5.6B
BS Liab Current Debt $3.0B $3.7B $2.3B $2.6B $1.6B
BS Liab Other Current $18.6B $19.7B $20.5B $22.6B $24.9B
BS Liab Total Current $37.0B $43.0B $47.8B $42.1B $42.7B
BS Liab Long Term Debt $61.6B $57.4B $61.5B $32.9B $36.2B
BS Liab Deferred Tax Liab $2.4B $2.1B $640.0M $1.0B $349.0M
BS Liab Other Noncurrent $14.7B $14.2B $16.5B $13.2B $9.7B
BS Liab Total $121.4B $124.9B $137.2B $101.3B $104.0B
BS Equity Preferred Stock $0 $27.0M $27.0M $0 $0
BS Equity Common Stock $481.0M $480.0M $478.0M $476.0M $473.0M
BS Equity APIC $94.5B $93.6B $92.6B $91.8B $90.6B
BS Equity Retained Earnings $114.6B $116.7B $118.4B $125.7B $103.4B
BS Equity Treasury Stock $115.0B $114.8B $114.5B $114.0B $111.4B
BS Equity AOCI $-8.1B $-7.8B $-8.0B $-8.3B $-5.9B
BS Equity NCI $299.0M $294.0M $274.0M $256.0M $262.0M
BS Equity Total $86.5B $88.2B $89.0B $95.7B $77.2B
BS Equity Total Liab and Equity $208.2B $213.4B $226.5B $197.2B $181.5B